Company: TVRD
Filing Date: 2025-01-17
Form Type: 8-K
Source: 0001104659-25-004517
Chunk: 0

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-17
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

Regained Compliance - Nasdaq Minimum Bid Price Requirement

As previously disclosed, on February 1, 2024,
Cara Therapeutics, Inc. (the" Company) received a notification letter from the Listing Qualifications Department (the
“Staff”) of The Nasdaq Stock Market (“ Nasdaq”) with respect to the Company’s
failure to maintain a minimum closing bid price of $1.00 per share on any business day over a thirty consecutive business day period,
as required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) ( “Rule 5450(a)(1)”).
As previously disclosed, the Company had been provided an initial period of 180 calendar days, or until July 30, 2024, to regain compliance
with Rule 5450(a)(1), which period was extended by Nasdaq by notification received on July 31, 2024 for an additional 180 calendar day
period ending January 27, 2025 to regain compliance with the same minimum closing bid price requirement for continued listing on the
Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (together with Rule 5450(a)(1), the “ Minimum Bid Price Requirement”).
Effective as of August 1, 2024, the listing of the Company’s common stock was transferred from the Nasdaq Global Market to the
Nasdaq Capital Market.